The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and Its Use in Treatment of Breast Cancer

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/978-3-319-13081-1_13
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC)

  2016cited by this paper
• Management of Metastatic Breast Cancer with Second-Generation Antibody–Drug Conjugates: Focus on Glembatumumab Vedotin (CDX-011, CR011-vcMMAE)

  2014cited by this paper
• GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity.

  2014cited by this paper
• Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer

  2013cited by this paper
• Novel Genes Associated with Colorectal Cancer Are Revealed by High Resolution Cytogenetic Analysis in a Patient Specific Manner

  2013cited by this paper
• Global estimates of cancer prevalence for 27 sites in the adult population in 2008

  2013cited by this paper
• Abstract P6-10-01: A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study

  2012cited by this paper
• Basal-like Breast Cancer—Characteristics, Risks, and Associations

  2012cited by this paper
• ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain with Angiogenic Properties

  2010cited by this paper
• Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer

  2010cited by this paper
• Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma.

  2010cited by this paper
• Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE).

  2010cited by this paper
• Physiological factors that regulate skin pigmentation

  2009cited by this paper
• Gpnmb is a melanosome‐associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD‐dependent fashion

  2009cited by this paper
• Immunological Approaches in the Treatment of Metastasized Breast Cancer

  2009cited by this paper
• A Phase (Ph) I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients (Pts) with Locally Advanced or Metastatic Breast Cancer (MBC).

  2009cited by this paper
• Osteoactivin Promotes Breast Cancer Metastasis to Bone

  2007cited by this paper
• Gpnmb Is Induced in Macrophages by IFN-γ and Lipopolysaccharide and Acts as a Feedback Regulator of Proinflammatory Responses1

  2007cited by this paper
• Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate (CR011-vcMMAE) targeting GPNMB

  2007cited by this paper
• CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.

  2006cited by this paper
• Glycoprotein Nonmetastatic Melanoma Protein B, a Potential Molecular Therapeutic Target in Patients with Glioblastoma Multiforme

  2006cited by this paper
• Expression of osteoactivin in rat and human liver and isolated rat liver cells.

  2005cited by this paper
• Osteoactivin upregulates expression of MMP-3 and MMP-9 in fibroblasts infiltrated into denervated skeletal muscle in mice.

  2005cited by this paper
• cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

  2003cited by this paper
• nmb, a novel gene, is expressed in low‐metastatic human melanoma cell lines and xenografts

  1995cited by this paper
• Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials.

  1992cited by this paper
• Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.

  1990cited by this paper

• Current Status and Perspectives in Marine Biodiscovery

  2017cites this paper